Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd Outcome of Board Meeting
Jubilant Life Sciences Ltd has informed BSE that the Board of Directors of the Company has, at its meeting held on February 07, 2017, has approved acquisition of 18,66,20,000 12% Optionally Convertible Non-cumulative Redeemable Preference Shares of Rs. 10 each of Jubilant Biosys Limited at par aggregating to Rs. 186.62 crore, subject to applicable laws. Change in Directorate
Jubilant Life Sciences Ltd has informed BSE that the following changes in the Board of Directors of the Company:1. Resignation of Mr. Shyamsundar Bang: Mr. Shyamsundar Bang has submitted his resignation as Executive Director of the Company on his superannuation from the services of the Company. The Board has, at its meeting held on February 07, 2017, accepted his resignation with immediate effect. He shall continue as Director of the Company till March 31, 2017.... Announces Q3 results (Standalone & Consolidated), Limited Review Report (Standalone & Consolidated), Results Press Release & Presentation for the Quarter ended December 31, 2016
Jubilant Life Sciences Ltd has announced the following results for the quarter ended December 31, 2016 The Unaudited Standalone results for the Quarter ended December 31, 2016:The Company has posted a net profit of Rs. 82.60 million for the quarter ended December 31, 2016 as compared to Rs. 289.50 million for the quarter ended December 31, 2015. Total Income has decreased from Rs. 6842.00 million for the quarter ended December 31,... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd Details of issue of Non-Convertible Debentures
Jubilant Life Sciences Ltd has informed BSE regarding Details of issue of Non-Convertible Debentures. Jubilant issue NCDs of INR 495 crores
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated January 27, 2017 titled "Jubilant issue NCDs of INR 495 crores". Jubilant Life gets responsible care certification
Jubilant Life Sciences, an integrated global pharmaceuticals and life sciences company, has received Responsible Care 14001:2013 certification' under the American Chemistry Council's Responsible... Credit Rating
Jubilant Life Sciences Ltd has informed BSE that the Company has received Credit Rating of Proposed IND AA- with a Stable Outlook from India Ratings & Research Private Limited for the proposed issue of Non-Convertible Debentures of Rs. 4,950 million. Issuance of Commercial Papers of Rs. 50 crore
Jubilant Life Sciences Ltd has informed BSE regarding "Issuance of Commercial Papers of Rs. 50 crore".